MicroRNAs in Dopamine Agonist-Resistant Prolactinoma

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• Dopamine agonists (DAs) are first-line treatment for prolactinomas.
• A significant percentage of patients exhibit resistance to DAs, with unclear mechanisms.
• Bromocriptine and cabergoline are common DAs, but resistance varies.

Purpose of the Study:

• To review the role of microRNAs (miRNAs) in dopamine agonist-resistant prolactinoma (DARP).
• To explore potential therapeutic targets for DARP based on miRNA dysregulation.

Main Methods:

• Literature review of studies on miRNAs and DARP.
• Analysis of evidence linking miRNAs to specific signaling pathways (TGF-β, D2R, E2/ER).

Main Results:

• MicroRNAs are frequently dysregulated in DARP.
• Dysregulated miRNAs potentially target TGF-β, dopamine 2 receptor (D2R), or estradiol (E2)/estrogen receptor (ER) pathways.
• The precise role and mechanism of miRNA dysregulation in DARP remain under investigation.

Conclusions:

• MicroRNA dysregulation is implicated in DARP pathogenesis.
• Targeting specific miRNAs or their affected pathways (D2R, TGF-β, E2/ER) may offer novel therapeutic strategies for DARP.
• Further research is needed to elucidate miRNA dysregulation mechanisms and validate therapeutic targets.